Hospitalized men with COVID-19 who meet the eligibility criteria will be informed about study and the potential risks. All the patients giving written informed consent will be randomized in 1:1 ratio to progesterone (100 mg SQ twice daily) plus standard of care or standard of care alone.
The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.